Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study

Valentina Corigliano, Anna Comparelli, Iginia Mancinelli, Benedetta Montalbani, Dorian A. Lamis, Antonella De Carolis, Denise Erbuto, Paolo Girardi, and Maurizio Pompili

1Department of Neurosciences, Unit of Psychiatry, Sapienza University of Rome, School of Medicine and Psychology, Via di Grottarossa 1035-39, 00198 Rome, Italy
2Department of Psychiatry and Behavioral Sciences, Emory School of Medicine, Grady Hospital, Atlanta, GA, USA
3Department of Neurosciences, Unit of Neurology, Sapienza University of Rome, School of Medicine and Psychology, Via di Grottarossa 1035-39, 00198 Rome, Italy

Correspondence should be addressed to Anna Comparelli; anna.comparelli@uniroma1.it

Received 30 May 2018; Revised 31 July 2018; Accepted 14 August 2018; Published 30 August 2018

Academic Editor: Hugo Schnack

Copyright © 2018 Valentina Corigliano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Long-acting injectable second-generation antipsychotics (LAI-SGA) are typically used to maintain treatment adherence in patients with chronic schizophrenia. Recent research suggests that they may also provide an effective treatment strategy for patients with early-phase disease. The aim of this study is to evaluate clinical and psychosocial outcomes among recent and long-term diagnosed schizophrenia outpatients treated with LAI-SGA during a follow-up period of 12 months. Stable schizophrenia patients receiving LAI-SGA with 5 or less years of illness duration (\(n = 10\)) were compared to those with more than 5 years of illness duration (\(n = 15\)). Clinical data was assessed through the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF), the Columbia Suicide Severity Rating Scale (C-SSRS), the Recovery Style Questionnaire (RSQ), and the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch. Recently diagnosed patients showed greater improvement versus patients diagnosed for more than 5 years in adjusted mean GAF score, in PANSS factor score for negative and depressive symptoms, and in severity and intensity of suicidal ideation. Our preliminary findings support the hypothesis that LAI-SGA may influence the course of the illness if administered at the early phase of the illness. However, replicate studies are needed, possibly with larger samples.

1. Introduction

Schizophrenia poses a significant burden to the patient, caregiver, and society in general. Additionally, mostly due to suicide deaths, patients diagnosed with schizophrenia have their life expectancy reduced by approximately 10 years [1].

Much of the deterioration in schizophrenia occurs within the first 5 years of disease onset [2], suggesting that the early stages are a critical period for effective treatment.

Treatment for schizophrenia aims to reduce the severity of symptoms, prevent the recurrence of episodes, and provide support to allow for an appropriate level of functioning. Given that up to half of patients suffering from schizophrenia may not take their medications as prescribed, treatment adherence is a major challenge [3], with serious consequences on the course of the illness [4–6]. Nonadherence is of particular significance to patients in the early phases of psychosis. As the disease progresses, deterioration in treatment responsiveness...
becomes more common, especially with standard oral antipsychotics. Long-acting injectable (LAI) second-generation antipsychotics were developed with the primary objective of addressing both hidden and overt nonadherence. Although LAI-SGA traditionally have been reserved for patients at later periods of their disease, increasingly, LAI-SGA are being suggested for early episodes of schizophrenia to reduce the risk of relapse and long-term disability associated with the chronic course of the illness [7–9]. Furthermore, available treatments are effective in reducing positive and affective symptoms; however, negative and cognitive symptoms, which affect global functioning and outcome, still represent an unmet need. Despite the importance of effective treating of negative symptoms, few studies have explored the changes in negative symptomatology among nonacute schizophrenia patients who switched to LAI-SGA from oral antipsychotics [10]. Thus, more research is needed to investigate this clinical outcome.

A recent review indicated a possible association between treatment with LAI-SGA and reduced suicide risk in schizophrenia [11], with LAI-SGA improving various risk factors for suicide. However, although there is a well-documented association between schizophrenia and suicide risk factors, there is a lack of studies investigating the efficacy as well as the effectiveness of LAI-SGA in suicide risk among schizophrenia patients.

Some researchers have proposed that social cognition deficits may be a schizophrenia vulnerability marker [12] affecting real-life functioning in people [13]. To date, no differences have been found in social emotion cognition task performance after treatment with LAI-SGAs in patients with schizophrenia [14]. However, the lack of empirical data on this relationship did not allow for definitive conclusions to be made.

In the treatment of patients with schizophrenia, the primary goal is traditionally clinical recovery, which includes remission of symptoms and functional improvement. The term personal recovery is used to describe the patient-based definition of recovery [15]. The construct of personal recovery has been developed based on narratives of individuals who have experienced mental illness [16]. To our knowledge, no studies have explored the effect of antipsychotic drugs on personal recovery.

The main aim of the present study is the evaluation of negative symptoms, social cognition, and global functioning 12 months after the initiation of treatment with LAI-SGA among patients who had a recent diagnosis of schizophrenia compared to long-term schizophrenia patients. As secondary outcome, we aim to compare changes in suicide risk and personal recovery between the two groups to determine LAI-SGA effectiveness on subjective well-being. We hypothesized that recently diagnosed patients would improve more than long-term diagnosed schizophrenia patients on psychiatric and psychosocial features affecting illness prognosis.

2. Materials and Methods

2.1. Subjects. We enrolled patients meeting the DSM-IV schizophrenia disorder based on the Structured Interview for DSM-IV Disorders-I (SCID-I) [17] who were administered long-acting antipsychotic treatment based on an attending physician's clinical judgment. Patients were recruited from the outpatient service of the Psychiatric Department of the Sant'Andrea Hospital, Rome. Patients were required to be clinically stable for a minimum of 4 months and receiving consistent doses of oral antipsychotic medication (excluding clozapine) for 4 weeks prior to study entry. Patients were allowed to continue on any prescribed antidepressants, anxiolytics, or mood stabilizers during the trial, provided they had been on a stable dose for 4 weeks before baseline.

Of the 35 eligible patients, 7 dropped out before completing the procedures and 3 were excluded from the follow-up because of the pharmacological treatment change over the observational period of the study, which left 25 to be included in the analyses (19 males, 6 female). Of the final sample of patients, 14 received treatment with paliperidone palmitate (PLAI), 2 with risperidone long-acting (RLAI), 2 with olanzapine pamoate (OLAI), and 7 with aripiprazole long-acting (ALAI). Six patients used cannabis (24%) and 9 reported suicidal ideation at the time of the assessment, two of which made a suicide attempt during the course of the illness. There was no change in the antipsychotic medication dosage during the course of the study. Two patients were hospitalized because of psychotic relapse, but they were not excluded because there was no change in the LAI treatment. Patients were categorized by the years of illness duration: those with 5 or less years of illness were classified as recent diagnosis schizophrenia (recent SZ) and those with more than 5 years of illness were classified as long-term diagnosis schizophrenia (long-term SZ). The total numbers of patients with at least 12-month follow-up in the recent diagnosis SZ and long-term diagnosis SZ groups were 10 and 15, respectively.

Patients were excluded based on the following criteria: (1) current or past comorbid diagnosis of autistic disorder or other pervasive developmental disorder, (2) history of severe head injury, (3) severe medical conditions or major neurological disorders, including mental retardation and dementia, and (4) any current drug abuse with the exception of cannabis, because of the high prevalence of its use among schizophrenia patients [18, 19]. Patients were tested at baseline and prospectively followed up to 12 months. Written informed consent was obtained from all participants after providing a complete description and explanation of the study. The study received approval from the hospital’s ethical committee.

2.2. Assessments. Data on sociodemographic and psychopathological variables were collected at clinical interview. Psychopathology was assessed with the PANSS [20]. As recommended by Wallwork et al. [21], we used the PANSS to extract the following 5 factors: (a) positive (POS) (P1, delusions; P3, hallucinatory behavior; P5, grandiosity; and G9, unusual thought content); (b) negative (NEG) (N1, blunted affect; N2, emotional withdrawal; N3, poor rapport; N4, passive withdrawal; N6, lack of spontaneity; and G7, motor retardation); (c) disorganized/concrete (DIS) (N5, difficulty in abstract thinking; P2, conceptual disorganization; and G11, poor attention); (d) excited (EXC) (P4, excitement;
P7, hostility; G8, uncooperativeness; and G14, poor impulse control); and (e) depressed (DEP) (G2, anxiety; G3, guilt feelings; and G6, depression).

Global functioning was assessed with the Global Assessment of Functioning (GAF) Scale [22]. The GAF assesses the psychological, social, and occupational functioning of a patient on a 100-point scale ranging from 1 (severe functional impairment) to 100 (optimal functioning), with higher scores indicating better functioning.

Suicide risk was assessed with the Columbia Suicide Severity Rating Scale (C-SSRS) [23] “Since Last Visit” version. The C-SSRS has four constructs relevant to recent suicidal ideation (SI): (1) severity (1= wish to be dead, 2= nonspecific active suicidal thoughts, 3= suicidal thoughts with methods, 4= suicidal intent, and 5= suicidal intent with plan); (2) intensity (sum across six items each rated 0 to 5: most severe ideation, frequency, duration, controllability, deterrents, and reason); (3) behavior; and (4) lethality.

Personal recovery was measured with the Recovery Style Questionnaire (RSQ) [24], a 39-item self-report measure, designed to reflect categories consistent with those developed by McGlashan et al. [25]. Thirteen scales were computed, with higher scores representing “integration” (i.e., a recovery style associated with better outcome, less depression, and better self-evaluation, as compared to a “sealing-over” style) [26]. Different from personal recovery, clinical recovery is related to improvement of symptoms and functioning.

Social cognition was assessed with the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch [27], which includes subscales rating which emotional strategy would be most effective for regulating the self and other people’s emotions. For each item, participants responded on the level of effectiveness of a list of options, ranging from 1 (very ineffective) to 5 (very effective), or the presence of a certain emotion, ranging from 1 (not at all) to 5 (present to a great extent).

2.3. Statistical Analysis. We examined differences in demographic characteristics and clinical features at baseline between the recent SZ and the long-term SZ patients. Then, we conducted Student’s t-tests to assess changes in psychopathological, functional, and personal resources and context-related features from baseline (T0) to follow-up (T1) in each group. An analysis of covariance model with group as a factor and baseline scores as a covariate was used to assess between-group changes from baseline to end point with no correction for multiplicity. Mean changes from baseline were reported as least squares means, adjusted for group and baseline values. A significance level of 0.05 was used for all statistical tests and two-tailed tests were applied. All analyses were conducted with the statistical package SPSS (version 17.0.2).

3. Results

The mean age was significantly lower in the recent SZ group compared to the long-term SZ group. No other differences in demographic variables were found between groups. The clinical variables in both groups were similar at baseline and no significant differences were found (Table 1). Considering pharmacological treatment, according to Gardner et al. [28], mean daily dose for antipsychotic medication in chlorpromazine-equivalents was 19.3 mg (DS=3.9) in recent SZ and 22.9 mg (DS=4.9) in long-term SZ, with no significant difference between the two dosages (T 2.41, df=23, p>0.05).

Thirty percent of recent SZ patients and 33% of long-term SZ patients received mood stabilizers at baseline, whereas 10% of recent SZ and 20% of long-term SZ received anxiolytic treatment at the same time. No patients in both groups received antidepressant at the baseline and during the course of the study.

In the recent SZ group, a significant improvement was found on the negative PANSS dimension, severity, and intensity of SI and on the RSQ (see Table 2). Both groups had a significant improvement on GAF score and PANSS factor score for positive and excitement symptoms from baseline to 12-month follow-up. There were no differences on MSCEIT scores from baseline to 12-month follow-up in either patient group. Mean changes in evaluated factors for both groups are reported in Table 2.

ANCOVA analyses showed greater improvement in GAF and in PANSS negative and depressive factor scores in the recent SZ group versus the long-term SZ group. The recent SZ group had lower severity and intensity SI after SGAI-LAI treatment compared to the long-term SZ group. No other statistically significant differences were found among groups (see Table 3).

4. Discussion

The aim of this pilot study was to compare clinical, cognitive, and psychosocial outcomes between recent and long-term diagnosed schizophrenia patients after 12 months with second-generation long-acting antipsychotic drugs. On the whole, our findings show the efficacy of LAI-SGA in improving the positive and excited symptoms and general functioning at 12 months of follow-up.

This is in line with most of the literature demonstrating the effectiveness of LAI-SGA in schizophrenia patients regardless of the stage of the illness [29–31].

Interestingly, in our study, schizophrenia patients at early phase of the illness seemed to benefit more from the use of LAI-SGA compared to chronic patients. In fact, only the group of recent SZ patients reported an improvement of negative symptoms, a reduction in intensity and severity of suicidal ideation, and a more effective recovery style. Furthermore, greatest improvements were found among those patients who started LAI-SGA within 5 years of diagnosis in PANSS negative and depressive factors, in global functioning, and in severity and intensity of SI. Benefits of early treatment have already been shown with oral antipsychotics [32, 33], whereas there are fewer studies examining the long-term benefits of LAI in recently diagnosed schizophrenia. Existing studies have demonstrated that recently diagnosed patients treated with LAI-SGA had a global higher treatment response and improved functioning as compared to chronic patients at six months of follow-up [10, 34, 35]. Unfortunately there are no studies examining the outcome of specific symptom.
Table 1: Demographics and baseline disease characteristics of Recent and Long-term diagnosed SZ group.

|                  | Recent SZ (n=10) | Long-term SZ (n=15) | Analyses |
|------------------|------------------|---------------------|----------|
|                  | Mean (SD)        | Mean T0 (SD)        | F        | df | p   |
| Age              | 25.7 (6.5)       | 43.3 (10.6)         | 3.618    | 23 | 0.001 |
| Years of education | 11.9 (2.1)     | 12.9 (2.4)          | 0.130    | 23 | 0.316 |
| Time since diagnoses (years) | 3.5 (1.3)       | 17.73 (9.4)         | 9.636    | 23 | 0.002 |
| GAF              | 43.6 (7.8)       | 40.1 (11.3)         | 0.797    | 23 | 0.408 |
| PANSS Pos        | 16.2 (6.8)       | 20.7 (6.9)          | 0.035    | 23 | 0.117 |
| PANSS Neg        | 17.5 (7.0)       | 21.1 (6.9)          | 0.045    | 23 | 0.834 |
| PANSS Gen        | 36.5 (7.1)       | 36.7 (11.2)         | 1.466    | 23 | 0.238 |
| PANSS Tot        | 70.2 (11.4)      | 78.5 (23.6)         | 3.985    | 23 | 0.058 |
| IS severity      | 1.9 (2.3)        | 1.1 (2.1)           | 1.007    | 23 | 0.378 |
| IS intensity     | 6.8 (8.4)        | 3.9 (7.1)           | 1.210    | 23 | 0.553 |
| RSQ              | 21.2 (6.1)       | 22.4 (3.9)          | 1.288    | 23 | 0.756 |
| Social cognition | 80.6 (7.9)       | 81.9 (12.1)         | 4.383    | 23 | 0.001 |

Table 2: Mean changes in clinical and psychosocial features from baseline to 12-month follow-up in recent schizophrenia and in long-term schizophrenia patients.

|                  | Recent SZ (n=10) | Long-term SZ (n=15) |
|------------------|------------------|---------------------|
|                  | Mean T0 (SD)/Mean T1 (SD) | Mean T0 (SD)/Mean T1 (SD) |
| GAF              | 43.6 (7.8)/56.4 (9.5)* | 40.1 (11.3)/49.0 (7.5)** |
| PANSS Pos        | 9.2 (4.6)/6.8 (3.8)* | 11.5 (4.5)/6.6 (2.5)** |
| PANSS Neg        | 13.7 (6.7)/11.5 (5.1)* | 16.7 (6.6)/15.1(5.0) |
| PANSS Dis/Con    | 7.0 (1.8)/5.8 (1.8) | 7.9 (2.8)/6.9 (2.6) |
| PANSS Exc        | 8.2 (3.8)/5.0 (1.9)* | 9.3 (5.4)/5.5 (2.4)** |
| PANSS Dep        | 6.8 (3.7)/5.8 (2.6) | 6.1 (3.4)/5.5 (2.9) |
| IS severity      | 1.9 (2.3)/0.5 (1.6)* | 1.13 (2.1)/0.5 (1.8) |
| IS intensity     | 6.8 (8.4)/1.2 (3.8)* | 3.9 (7.1)/2.5 (5.5) |
| RSQ              | 21.2 (6.1)/23.4 (6.6)* | 22.4 (3.9)/23.6 (5.1) |
| Social cognition | 80.6 (8.0)/83.5 (14.9) | 81.9 (12.1)/84.3 (8.4) |

*= p<0.05; ** = p<0.001.

domains through the analysis of single PANSS factors, nor the suicidal ideation or other clinical variables that influence the outcome of the disease. Moreover, in the majority of studies, follow-up is limited to six months, which is a relatively short outcome making the comparison weaker. Nonetheless, our findings are in line with other studies that show a global improvement in the recent diagnosed schizophrenia group.

Improvement of negative symptoms in recently diagnosed patients is the most important finding of our study. Negative symptoms have long been conceptualized as a core aspect of schizophrenia, playing a key role in the functional outcome of the disorder and representing a significant unmet need, mostly if persistent over the first episode of psychosis [36].

There are several indications that second-generation antipsychotics have promyelinating [37] and lipogenic effects [38] of importance to the therapeutic response in psychotic disorders. A recent study found a significant relationship between the increase in HDL and decrease in negative symptoms in FEP patients after one year of antipsychotic medication, independently of weight change [39]. It has been speculated that HDL in serum could be considered an indirect proxy for cholesterol in the brain, where improved supply could play a positive role in myelination. Patients with schizophrenia have reduced myelination in the brain [40–42], and in vivo MRI studies have demonstrated in FEP promyelinating effects of second-generation antipsychotic drugs specifically in their long-acting formulation [37,43,44] that in part could be related to their lipid-stimulating effects [39,45].

The second noteworthy finding of the present study is the reduction of severity and intensity of SI only in the early phase of the disease. This finding supports the proposals advanced in a recent review [11] that LAI treatments may potentially be an important strategy in suicide prevention by indirectly acting on a range of suicide risk factors in schizophrenia.

Suicide-related mortality is higher among subjects recently diagnosed with schizophrenia (≤5 years from diagnosis) [46]. Symptoms of depression are consistently supported by factors involved in suicidal ideation [47,48]. Even if suicidal ideation may be present in different stages of disease, some differences have been described between the risk of suicide in patients experiencing first episode of psychosis and those with long-term schizophrenia. Over
the course of the illness, suicide risk is related to the loss of social role and functioning mostly due to neuropsychological impairment. On the other hand, in the early phase of the illness, suicidal ideation may be related to the impact of first symptom experiences, to the valence of personal meaning-making, and to the consequences of the diagnosis of psychosis, all being issues concerning the subjective experience of the illness.

Beyond the reduction of depressive symptoms, the reduction of suicidal ideation may be the result of the improvement of personal recovery style. In fact, whereas clinical recovery improved in both groups, personal recovery improved only in the recent SZ group. In schizophrenia, personal recovery interferes with both symptom reduction and social functioning [49] and it has been recently found that suicide ideation is less prevalent among individuals with schizophrenia that self-reported greater recovery [50]. McGlashan [51] conceptualized the subjective experience of psychosis as a continuum of recovery styles. Two distinct recovery styles (i.e., “integration” and “sealing over”) have been defined [24, 25, 51]. Patients who employ the “sealing-over” recovery style make more negative self-evaluations and perceive their parents as significantly less caring than those with the “integration” style [52]. This latter style seems to favor recovery [51]. At one end of the continuum lies “integration,” which is exemplified by persons who show an interest in their psychotic experiences and appear eager to discuss and learn more about them and to gain a meaningful perspective on them. At the other end of the continuum is “sealing over,” exemplified by persons who have difficulty recalling or describing the phase of acute psychosis, deny the existence and/or severity of their illnesses, and expect to return rapidly to normal functioning. From the subjective perspective, recovery is driven by individual’s lives, peer support, and subjective experiences of mental illness and recovery and entails much more than managing symptoms. Precisely for that reason, when recovery style tends toward integration, it may positively affect suicidal ideation. Thus, we suggest that outcome measures in clinical practice, which currently focus on symptom remission and functioning, should be extended to include personal recovery. Several limitations have to be taken into account. First, the small sample size increased the risk of biased findings. However, given the pilot nature of the present study, the results obtained in this investigation should be regarded as preliminary. Second, as the study was not randomized, a selection bias cannot be ruled out. Nevertheless, the selection of a real-life, noninterventional study design allows obtaining data applicable to daily clinical practice. Lastly, the definitions of “recent” versus “long-term” schizophrenia are arbitrary time points that may not take into account potential differences in treatment duration and history prior to the start of LAI-SGA. Indeed, much of the deterioration in schizophrenia occurs within the first 5 years of disease onset [32], suggesting that the first stage within 5 years is a critical period for effective treatment.

The major strength of this study is the use of the PANSS five-factor consensus model as outcome parameter, instead of considering clinical global measures. Other studies have focused on first-episode schizophrenia or have been limited to 6-month duration [53–55], whereas this study has a longer follow-up time.

To our knowledge, this pilot study is the first one providing initial evidence that LAI-SGA specifically improves negative symptoms, suicidal ideation, and personal recovery in the early phase of the illness and supports the hypothesis that LAI-SGA may potentially modify the course of the illness if administered at first episode. Studies on the pathophysiology of schizophrenia suggest that clinical deterioration and “deficit processes” may be irreversible if left untreated, resulting in further functional decline and neurological impairment. Replicability of our findings with larger samples is a crucial next step in order to accurately determine the potential benefit of LAI-SGA to address negative symptoms and suicidal ideation in the early phase of schizophrenia.

5. Conclusions

In this pilot study we found that, in recent diagnosed schizophrenia negative symptoms, suicidal ideation and personal recovery improved with LAI-SGA treatment, with more improvements on global functioning and negative and depressive symptoms compared to long-term diagnosed schizophrenia, supporting the hypothesis that LAI-SGA may influence the course of the illness if administered at first episode.
episode. However, replicate studies are needed, possibly with larger samples.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] P. Piotrowski, T. M. Gondek, A. Król’ca-Dere˙gowska, B. Misiak, T. Adamowski, and A. Kieja, “Causes of mortality in schizophrenia: An updated review of European studies,” Psychiatria Danubina, vol. 29, no. 2, pp. 108–120, 2017.

[2] J. A. Lieberman, D. Perkins, A. Belger et al., “The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches,” Biological Psychiatry, vol. 50, no. 11, pp. 884–897, 2001.

[3] M. Nosé, C. Barbui, and M. Tansella, “How often do patients with psychosis fail to adhere to treatment programmes? A systematic review,” Psychological Medicine, vol. 33, no. 7, pp. 1149–1160, 2003.

[4] P. Haddad, C. Brain, and J. Scott, “Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies,” Patient Related Outcome Measures, vol. 5, p. 43, 2014.

[5] M. Narasimhan, C. U. Pac, N. Masand, and P. Masand, “Partial compliance with antipsychotics and its impact on patient outcomes,” International Journal of Psychiatry in Clinical Practice, vol. 11, no. 2, pp. 102–111, 2007.

[6] R. J. Wyatt, “Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia,” Schizophrenia Research, vol. 5, no. 3, pp. 201–202, 1991.

[7] R. J. Wyatt and J. Henter, “Rationale for the study of early intervention,” Schizophrenia Research, vol. 51, no. 1, pp. 69–76, 2001.

[8] S. J. Keith and J. M. Kane, “Partial compliance and patient consequences in schizophrenia: our patients can do better,” Journal of Clinical Psychiatry, vol. 64, no. 11, pp. 1308–1315, 2003.

[9] P. Chue and R. Emsley, “Long-acting formulations of atypical antipsychotics: Time to reconsider when to introduce depot antipsychotics,” CNS Drugs, vol. 21, no. 6, pp. 441–448, 2007.

[10] L. Hargarter, P. Bergmans, P. Cherubin et al., “Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia,” Expert Opinion on Pharmacotherapy, vol. 17, no. 8, pp. 1043–1053, 2016.

[11] M. Pompei, L. Orsolini, D. A. Lamis et al., “Suicide prevention in schizophrenia: Do long-acting injectable antipsychotics (LAIs) have a role?” CNS and Neurological Disorders - Drug Targets, vol. 16, no. 4, pp. 454–462, 2017.

[12] M. Sprong, P. Schothorst, E. Vos, J. Hox, and H. Van Engeland, “Theory of mind in schizophrenia: Meta-analysis,” The British Journal of Psychiatry, vol. 191, no. JULY, pp. 5–13, 2007.

[13] S. Galderisi, A. Rossi, P. Rocca et al., “The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia,” World Psychiatry, vol. 13, no. 3, pp. 275–287, 2014.

[14] Y. Koshikawa, Y. Takekita, M. Kato et al., “The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: A 6-month, open-label, randomized controlled pilot trial,” Neuropsychobiology, vol. 73, no. 1, pp. 35–42, 2016.

[15] P. E. Deegan, “Recovery as a self-directed process of healing and transformation,” Occupational Therapy in Mental Health, vol. 17, no. 3-4, pp. 5–21, 2001.

[16] S. Mead and M. E. Copeland, “What recovery means to us: consumers’ perspectives,” Community Mental Health Journal, vol. 36, no. 3, pp. 315–328, 2000.

[17] M. B. First, R. L. Spitzer, J. B. W. Williams, and M. Gibbon, Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version, American Psychiatric Press, Washington, DC, USA, 1997.

[18] R. Nesvag, G. P. Knudsen, I. J. Bakken et al., “Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study,” Social Psychiatry and Psychiatric Epidemiology, vol. 50, no. 8, pp. 1267–1276, 2015.

[19] W. Hall and L. Degenhardt, “Cannabis use and psychosis: A review of clinical and epidemiological evidence,” Australian & New Zealand Journal of Psychiatry, vol. 34, no. 1, pp. 26–34, 2000.

[20] S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987.

[21] R. S. Wallwork, R. Fortgang, R. Hashimoto, D. R. Weinberger, and D. Dickinson, “Searching for a consensus five-factor model of the positive and negative Syndrome Scale for schizophrenia,” Schizophrenia Research, vol. 137, no. 1–3, pp. 246–250, 2012.

[22] I. M. Aas, “Global Assessment of Functioning (GAF): Properties and frontier of current knowledge,” Annals of General Psychiatry, vol. 7, pp. 9–20, 2010.

[23] K. Posner, G. K. Brown, B. Stanley et al., “The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults,” The American Journal of Psychiatry, vol. 168, no. 12, pp. 1266–1277, 2011.

[24] M. Drayton, M. Birchwood, and P. Trower, “Early attachment experience and recovery from psychosis,” The British Journal of Clinical Psychology, vol. 37, no. 3, pp. 269–284, 1998.

[25] T. H. McGlashan, S. T. Levy, and W. T. Carpenter, “Integration and Sealing Over: Clinically Distinct Recovery Styles From Schizophrenia,” Archives of General Psychiatry, vol. 32, no. 10, pp. 1269–1272, 1975.

[26] N. Poloni, C. Callegari, A. Buzzi et al., “The Italian version of ISOS and RSQ, two suitable scales for investigating recovery style from psychosis,” Epidemiologia e Psichiatria Sociale, vol. 19, no. 4, pp. 352–359, 2010.

[27] J. D. Mayer, P. Salovey, D. R. Caruso, and G. Sitarenios, “Measuring emotional intelligence with the MSCEIT v2.0,” Emotion, vol. 3, no. 1, pp. 97–105, 2003.

[28] D. M. Gardner, A. L. Murphy, H. O’Donnell, F. Centorrino, and R. J. Baldessarini, “International consensus study of antipsychotic dosing,” The American Journal of Psychiatry, vol. 167, no. 6, pp. 686–693, 2010.

[29] A. Schreiner, A. Caspi, P. Bergmans et al., “Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, intervention study,” Psychopharmacology, vol. 234, no. 1, pp. 3–13, 2017.
[30] E. Giraud-Baro, D. Dassa, F. De Vathaire, R. P. Garay, and J. Obeid, “Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: Functional recovery in remitted vs. non-remitted patients (the EVEREST prospective observational cohort study),” *BMC Psychiatry*, vol. 16, no. 1, 2016.

[31] T. Peters-Strickland, C. Zhao, P. P. Perry et al., “Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics,” *CNS Spectrums*, vol. 21, no. 6, pp. 460–465, 2016.

[32] J. A. Lieberman, G. Tollefson, M. Tohen et al., “Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol,” *The American Journal of Psychiatry*, vol. 160, no. 8, pp. 1396–1404, 2003.

[33] N. Schooller, J. Rabinowitz, M. Davidson et al., “Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial,” *The American Journal of Psychiatry*, vol. 162, no. 5, pp. 947–953, 2005.

[34] V. Dubois, J. Peuskens, P. Geerts, and J. Detraux, “Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: Results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of Remission in Schizophrenia with risperidone (TIMOREs),” *Early Intervention in Psychiatry*, vol. 8, no. 1, pp. 39–49, 2014.

[35] J. M. Olivares, J. Peuskens, J. Pecenak, S. Resseler, A. Jacobs, and K. S. Akhras, “Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenic patients: Results from a multinational electronic registry,” *Current Medical Research and Opinion*, vol. 25, no. 9, pp. 2197–2206, 2009.

[36] S. Galderisi, A. Mucci, I. Bitter et al., “Persistent negative symptoms in first-episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial,” *European Neuropsychopharmacology*, vol. 23, no. 3, pp. 196–204, 2013.

[37] G. Bartzokis, P. H. Lu, K. H. Nuechterlein et al., “Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia,” *Schizophrenia Research*, vol. 93, no. 1-3, pp. 13–22, 2007.

[38] V. M. Steen, S. Skrede, T. Polushina et al., “Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment,” *European Neuropsychopharmacology*, vol. 27, no. 6, pp. 589–598, 2017.

[39] P. B. Gjerde, I. Dieset, C. Simonsen et al., “Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis,” *Schizophrenia Research*, 2017.

[40] K. L. Davis, D. G. Stewart, J. I. Friedman et al., “White Matter Changes in Schizophrenia,” *Archives of General Psychiatry*, vol. 60, no. 5, p. 443, 2003.

[41] H.-G. Bernstein, J. Steiner, P. C. Guest, H. Dobrowolny, and B. Bogerts, “Glial cells as key players in schizophrenia pathology: Recent insights and concepts of therapy,” *Schizophrenia Research*, vol. 161, no. 1, pp. 4–18, 2015.

[42] M. I. Mighdoll, R. Tao, J. E. Kleinman, and T. M. Hyde, “Myelin, myelin-related disorders, and psychosis,” *Schizophrenia Research*, vol. 161, no. 1, pp. 85–93, 2015.

[43] G. Bartzokis, P. H. Lu, S. B. Stewart et al., “In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia,” *Schizophrenia Research*, vol. 113, no. 2-3, pp. 322–331, 2009.

[44] G. Bartzokis, P. H. Lu, E. P. Raven et al., “Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia,” *Schizophrenia Research*, vol. 140, no. 1-3, pp. 122–128, 2012.

[45] H. L. Cai, Q. Y. Tan, P. Jiang et al., “A potential mechanism underlying atypical antipsychotics-induced lipid disturbances,” *Translational Psychiatry*, vol. 5, no. 10, pp. e661–e661, 2015.

[46] W. W. Fleischhacker, J. M. Kane, J. Geier et al., “Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial,” *Journal of Clinical Psychiatry*, vol. 75, no. 3, pp. e184–e190, 2014.

[47] K. Hor and M. Taylor, “Suicide and schizophrenia: a systematic review of rates and risk factors,” *Journal of Psychopharmacology*, vol. 24, no. 4, pp. 81–90, 2010.

[48] P. Bosanac and D. J. Castle, “Schizophrenia and depression,” *Medical Journal of Australia*, vol. 199, no. 6, pp. S36–S39, 2013.

[49] A. Rossi, S. Galderisi, P. Rocca et al., “The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study,” *European Archives of Psychiatry and Clinical Neurosciences*, vol. 267, no. 4, pp. 285–294, 2017.

[50] D. R. Jahn, J. E. Devylder, A. L. Drapalski, D. Medoff, and L. B. Dixon, “Personal Recovery as a Protective Factor Against Suicide Ideation in Individuals with Schizophrenia,” *The Journal of Nervous and Mental Disease*, vol. 204, no. 11, pp. 827–831, 2016.

[51] T. H. McGlashan, “Recovery style from mental illness and long-term outcome,” *The Journal of Nervous and Mental Disease*, vol. 175, no. 11, pp. 681–685, 1987.

[52] L. Tait, M. Birchwood, and P. Trower, “Adapting to the challenge of psychosis: Personal resilience and the use of sealing-over (avoidant) coping strategies,” *The British Journal of Psychiatry*, vol. 185, pp. 410–415, 2004.

[53] E. Parellada, “Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations,” *Psychopharmacology Bulletin*, vol. 40, pp. 82–100, 2007.

[54] E. Parellada, R. Andrezina, V. Milanova et al., “Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable,” *Journal of Psychopharmacology*, vol. 19, no. 5, pp. 5–14, 2005.

[55] B. Kim, S.-H. Lee, T. K. Choi et al., “Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting,” *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, vol. 32, no. 5, pp. 1231–1235, 2008.